DSIP — questions, answered plainly.

DSIP (delta sleep-inducing peptide) is an endogenous nine-residue peptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in the 1970s from rabbit cerebral venous blood during electrical sleep stimulation.

The peer-reviewed primary literature on DSIP is concentrated in the 1970s–2000s. The Graf 1984 and 1986 reviews (PMIDs 6145137, 3550726) and the Pollard 2001 review (PMID 11437870) are the most accessible secondary sources summarising the field.

Historical research described DSIP as inducing delta-sleep states across multiple species, but with a U-shaped dose-response. Effects on neurotransmitter and hormone levels are also described. The mechanism remains incompletely characterised in the published literature.

No. DSIP is not approved as a medicine in any jurisdiction. Modern controlled human trials are limited or absent from major peer-reviewed databases.

Most published DSIP research dates from the 1970s–2000s, before modern pharmacokinetic and trial design standards. Interest declined as alternative sleep-pharmacology approaches developed. This profile cites the foundational reviews; recent primary research is sparse.

Most cited literature is from the 1970s–2000s. The mechanism and clinical relevance remain incompletely characterised. DSIP is not approved as a medicine.